Amgen Inc. $AMGN Shares Sold by CHICAGO TRUST Co NA

CHICAGO TRUST Co NA decreased its stake in Amgen Inc. (NASDAQ:AMGN) by 60.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,152 shares of the medical research company’s stock after selling 4,824 shares during the period. CHICAGO TRUST Co NA’s holdings in Amgen were worth $889,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Wealth Preservation Advisors LLC acquired a new stake in shares of Amgen during the 1st quarter valued at approximately $25,000. Legacy Investment Solutions LLC purchased a new position in Amgen in the 2nd quarter valued at approximately $27,000. CBIZ Investment Advisory Services LLC raised its holdings in Amgen by 1,214.3% during the first quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company’s stock worth $29,000 after purchasing an additional 85 shares during the last quarter. Evelyn Partners Investment Management LLP acquired a new position in Amgen during the second quarter worth $32,000. Finally, Howard Hughes Medical Institute purchased a new stake in Amgen during the second quarter worth $32,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Murdo Gordon sold 6,879 shares of the stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the transaction, the executive vice president directly owned 41,923 shares in the company, valued at $14,120,924.09. This represents a 14.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Rachna Khosla sold 890 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total transaction of $299,253.60. Following the completion of the sale, the senior vice president owned 7,082 shares of the company’s stock, valued at approximately $2,381,251.68. The trade was a 11.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 10,908 shares of company stock valued at $3,674,966. Insiders own 0.76% of the company’s stock.

Wall Street Analysts Forecast Growth

AMGN has been the subject of several research reports. Bank of America lifted their price target on Amgen from $261.00 to $272.00 and gave the stock an “underperform” rating in a research note on Friday, September 26th. Weiss Ratings restated a “buy (b)” rating on shares of Amgen in a report on Monday, December 15th. Raymond James Financial started coverage on shares of Amgen in a report on Wednesday, September 3rd. They issued a “market perform” rating on the stock. The Goldman Sachs Group reiterated a “buy” rating on shares of Amgen in a research report on Tuesday, November 25th. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on Amgen from $280.00 to $285.00 and gave the stock a “hold” rating in a research report on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Amgen currently has an average rating of “Moderate Buy” and a consensus price target of $332.85.

Amgen Stock Performance

NASDAQ:AMGN opened at $327.38 on Friday. Amgen Inc. has a 1-year low of $257.05 and a 1-year high of $346.38. The firm has a 50 day simple moving average of $319.32 and a 200-day simple moving average of $300.20. The firm has a market cap of $176.29 billion, a PE ratio of 25.30, a P/E/G ratio of 2.96 and a beta of 0.45. The company has a debt-to-equity ratio of 5.45, a current ratio of 1.28 and a quick ratio of 0.99.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, topping the consensus estimate of $5.01 by $0.63. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The firm had revenue of $9.56 billion during the quarter, compared to analysts’ expectations of $8.98 billion. During the same period in the previous year, the company earned $5.58 EPS. Amgen’s revenue for the quarter was up 12.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, equities analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be given a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 3.1%. This is a boost from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date is Friday, February 13th. Amgen’s dividend payout ratio (DPR) is currently 73.57%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.